A decade of writings on drug marketing and the attendant rules, tech and market forces (for Pharmaceutical Commerce):
- Medical marijuana looks for a place in conventional drug distribution: A chronicle of pharma’s early strategies for turning the increasingly legal weed into money, and the gnarly market, legislative and regulatory forces involved.
- CSOs broaden their palette of service offerings: How and why Big Pharma outsources sales reps to contract sales organizations (CSOs), and its retrenchment into more core pursuits.
- Animal-health pharmaceuticals are jumping the ethical channel: Big Pharma’s quest to balance their business with veterinarians, who bemoan their loss of product exclusivity to big-box stores and online pet pharmacies…and some unscrupulous players.
- Aggregate Spending rules arrive, but industry is still gearing up: How the Physicians Payment Sunshine Act, part of the Affordable Care Act of 2010, required Big Pharma to report payments (or extravagant bribes, say some) to doctors.
- With coupons, pharma is saying ‘let’s make a deal’ to consumers: The dynamics leading to integrated loyalty, coupon and voucher programs in the name of patient adherence, and profits.
- More published news, as cited on my blog: ‘Dragon’s blood’ used to treat canine cancer patients . . . Yummy science: 3D-printing of human ‘liver strips’ . . . Zevacor’s new cyclotron from IBA to offer new hope…in 2016 . . . more.